SEC Contract Filing

Filing Date: 2020-06-22

Document Content:
<DOCUMENT>
<TYPE>EX-10.39
<SEQUENCE>14
<FILENAME>ex10_39.htm
<DESCRIPTION>EXHIBIT 10.39
<TEXT>
<HTML>
<HEAD>
 <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 3in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.15pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="image_002.gif" ALT="">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 3in; text-indent: 0.5in; text-align: right">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 3in; text-indent: 0.5in; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
26, 2020</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Via
Electronic Mail</I></B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Generex
Biotechnology Corporation</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10102
USA Today Way</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Miramar,
FL 33025</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
Joseph Moscato, Chairman &amp; CEO</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re:&#9;<U>Retainer
for Legal Representation</U></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dear
Mr. Moscato:</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reference
is made to our letters dated December 5, 2019 (the &ldquo;<B>December 2019 Retainer</B>&rdquo;), pursuant to which you engaged
Carmel, Milazzo &amp; Feil LLP (the &ldquo;<B>Firm</B>&rdquo;) to represent your subsidiary, NuGenerex Immuno-Oncology, Inc, in
connection with, among other things, the preparation and filing of an S-1 Registration Statement (the &ldquo;<B>NuGenerex S-1
Registration Statement</B>&rdquo;) and March 18, 2020 (the &ldquo;<B>March 2020 Retainer</B>&rdquo; and together with the December
2019 Retainer, the &ldquo;<B>Retainers</B>&rdquo;), pursuant to which you engaged us to represent you in connection with, among
other things, the preparation and filing of a registration statement on Form S-1 (the &ldquo;<B>Generex S-1 Registration Statement</B>&rdquo;).
This letter consolidates, revises and supersedes the terms of our engagement under the Retainers and provides for the payment
of our fees for legal work we have already performed under the Retainers and for legal work to be performed under this letter.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
letter sets forth our understanding whereby Generex Biotechnology Corporation (&ldquo;<B>Generex</B>&rdquo; or the &ldquo;<B>Company</B>&rdquo;
or &ldquo;<B>you</B>&rdquo;) has engaged Carmel, Milazzo &amp; Feil LLP (the &ldquo;<B>Firm</B>&rdquo;) to represent (i) the Company
in connection with (a) the preparation and filing with the Securities and Exchange Commission (the &ldquo;<B>SEC</B>&rdquo;) of
a registration statement on Form S-1 (the &ldquo;<B>Generex S-1 Registration Statement</B>&rdquo;) for the registration of preferred
stock and warrants; (b) the preparation of transaction documents and the legal work required to authorize preferred stock (the
&ldquo;<B>Financing</B>&rdquo;); and (c) the preparation and filing of an application to quote its securities on a national exchange
(all of the matters described in clause (i), the &ldquo;<B>Generex Matters</B>&rdquo;) and (ii) NuGenerex Immuno-Oncology, Inc.,
a subsidiary of the Company (&ldquo;<B>NGIO</B>&rdquo;) , in connection with (a) the preparation and filing of a registration
statement on Form 10 (the &ldquo;<B>Form 10 Registration Statement</B>&rdquo;) for the registration of its common stock under
Section 12(g) of the Securities Act of 1933; (b) the preparation and filing with the SEC of a registration statement on Form S-1
(the &ldquo;<B>NGIO S-1 Registration Statement</B>&rdquo;) for the registration of common stock; and (c) the preparation and filing
of an application to quote its securities on a national exchange (all of the matters described in clause (ii), the &ldquo;<B>NGIO
Matters</B>&rdquo; and